Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: Feb 12, 2025
– Anticipate topline data from pivotal Advance-HTN trial in March 2025 and pivotal Phase 3 Launch-HTN trial in mid first half of 2025 –
– Completed enrollment in Explore-CKD Phase 2 trial and anticipate delivering topline data in Q2 2025 –
Read more at globenewswire.com10.52
-0.02 (-0.19%)
Find more stocks in the Stock Screener
MLYS Latest News and Analysis
2 days ago - ChartmillWhich stocks are moving after the closing bell on Friday?Discover the top movers in Friday's after-hours session and stay informed about the post-market dynamics.
